http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2342365-C
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_884170daee0baff8400371fa096c4d27 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-967 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S436-819 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S436-809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-973 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-323 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T436-104165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T436-105831 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-324 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-721 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-92 |
| filingDate | 1999-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2008-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_413f0eca9b51ba6114701f7833aa4100 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3eb583abb3dca737901da03a586add5 |
| publicationDate | 2008-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2342365-C |
| titleOfInvention | Detection and determination of the stages of coronary artery disease |
| abstract | A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stage s of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. Th e diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a samp le from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinical ly significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardi al infarction is indicated by the clinically significant presence of a third marker in a sample from the patient. Preferably the first marker comprises OxLDL, the second marker comprises MDA-modified LDL, and the third marker is a troponin. Preferably the OxLDL and MDA-modifi ed LDL are detected using monoclonal antibodies that can detect the presence of those markers in undiluted human plasma at concentrations as low as 0.02 milligrams/deciliter. |
| priorityDate | 1998-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 354.